Aprea Banks $51m Series B To Tackle 'Holy Grail' Of Oncology
This article was originally published in Scrip
Aprea AB, which is targeting the "holy grail" of anticancer research – the p53 tumor suppressor protein – and has the former head of oncology drug discovery of Bristol-Myers Squibb as its executive chair, has raised SEK 437m ($51m) in a series B financing.
You may also be interested in...
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.